To further explore the mechanisms that contribute to the refractoriness of myeloma cells toward CD26mAb therapy, we assessed the levels of complement inhibitory proteins (CIP) CD55 and CD59 in myeloma cells incubated with one of five HDACi for 48 hours. The gene discussed is CD59; the disease is plasma cell myeloma.